Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Что нового появилось в лечении пациента с сахарным диабетом и сердечно-сосудистыми заболеваниями: взгляд кардиологов
Что нового появилось в лечении пациента с сахарным диабетом и сердечно-сосудистыми заболеваниями: взгляд кардиологов
Бондаренко И.З., Бубнова М.Г. Что нового появилось в лечении пациента с сахарным диабетом и сердечно-сосудистыми заболеваниями: взгляд кардиологов. CardioСоматика. 2018; 9 (2): 24–30. DOI: 10.26442/2221-7185_2018.2.24-30
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В представленном обзоре обсуждается современная тактика лечения больных сахарным диабетом типа 2. Обсуждаются результаты крупного международного плацебо-контролируемого рандомизированного клинического исследования EMPA-REG OUTCOME с применением эмпаглифлозин-селективного ингибитора натрийзависимого переносчика глюкозы 2-го типа. Данный препарат стал первым сахароснижающим препаратом, доказавшим не только явные преимущества по безопасности влияния на сердечно-сосудистую систему, но и значимое положительное кардиопротективное влияние у больных сахарным диабетом типа 2. Представлены показания к его назначению в клинической практике.
Ключевые слова: сахарный диабет, сахароснижающая терапия, эмпаглифлозин, сердечно-сосудистые заболевания.
Key words: diabetes mellitus, hypoglycemic therapy, empagliflozin, cardiovascular diseases.
Ключевые слова: сахарный диабет, сахароснижающая терапия, эмпаглифлозин, сердечно-сосудистые заболевания.
________________________________________________
Key words: diabetes mellitus, hypoglycemic therapy, empagliflozin, cardiovascular diseases.
Полный текст
Список литературы
1. Standards of Medical Care in Diabetes. Diabetes care 2015; 38 (Suppl. 1). DOI: 10.2337/dc15-S001
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
3. ACCORD Study Group et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99 (12A): 21i–33i.
4. Patel A, Chalmers J, Poulter N. ADVANCE: action in diabetes and vascular disease. J Hum Hypertens 2005; 19 (Suppl. 1): S27–32.
5. Gerstein HC, Bosch J, Dagenais GR et al. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319–28.
6. White WB, Cannon CP, Heller SR et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Мed 2013; 369: 1327–35.
7. Scirica BM, Bhatt DL et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Мed 2013; 369: 1317–26.
8. Green JB, Bethel MA, Armstrong PW et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Мed 2015; 373 (3): 232–42.
9. Zinman B, Wanner C, Lachin JM. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Мed 2015; 373: 2117–28.
10. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375 (4): 323–34.
11. Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129 (5): 587–97.
12. Skrtic M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 2015; 24 (1): 96–103.
13. Lytvyn Y, Skrtic M, Yang GK et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2015; 308 (2): F77–83.
14. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Failure 2016; 18 (8): 891–975.
15. Verma S, Mazer D, Fitchett D et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOMER randomised trial. Diabetologia 2018; doi.org/10.1007/s00125-018-4644-9
16. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой, А.Ю.Майорова. 8-й вып. М.: УП ПРИНТ, 2017. DOI: 10.14341/DM20171S8 / Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi, A.Iu.Maiorova. 8-i vyp. M.: UP PRINT, 2017. DOI: 10.14341/DM20171S8 [in Russian]
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
3. ACCORD Study Group et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99 (12A): 21i–33i.
4. Patel A, Chalmers J, Poulter N. ADVANCE: action in diabetes and vascular disease. J Hum Hypertens 2005; 19 (Suppl. 1): S27–32.
5. Gerstein HC, Bosch J, Dagenais GR et al. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319–28.
6. White WB, Cannon CP, Heller SR et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Мed 2013; 369: 1327–35.
7. Scirica BM, Bhatt DL et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Мed 2013; 369: 1317–26.
8. Green JB, Bethel MA, Armstrong PW et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Мed 2015; 373 (3): 232–42.
9. Zinman B, Wanner C, Lachin JM. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Мed 2015; 373: 2117–28.
10. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375 (4): 323–34.
11. Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129 (5): 587–97.
12. Skrtic M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 2015; 24 (1): 96–103.
13. Lytvyn Y, Skrtic M, Yang GK et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2015; 308 (2): F77–83.
14. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Failure 2016; 18 (8): 891–975.
15. Verma S, Mazer D, Fitchett D et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOMER randomised trial. Diabetologia 2018; doi.org/10.1007/s00125-018-4644-9
16. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi, A.Iu.Maiorova. 8-i vyp. M.: UP PRINT, 2017. DOI: 10.14341/DM20171S8 [in Russian]
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
3. ACCORD Study Group et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99 (12A): 21i–33i.
4. Patel A, Chalmers J, Poulter N. ADVANCE: action in diabetes and vascular disease. J Hum Hypertens 2005; 19 (Suppl. 1): S27–32.
5. Gerstein HC, Bosch J, Dagenais GR et al. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319–28.
6. White WB, Cannon CP, Heller SR et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Мed 2013; 369: 1327–35.
7. Scirica BM, Bhatt DL et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Мed 2013; 369: 1317–26.
8. Green JB, Bethel MA, Armstrong PW et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Мed 2015; 373 (3): 232–42.
9. Zinman B, Wanner C, Lachin JM. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Мed 2015; 373: 2117–28.
10. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375 (4): 323–34.
11. Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129 (5): 587–97.
12. Skrtic M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 2015; 24 (1): 96–103.
13. Lytvyn Y, Skrtic M, Yang GK et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2015; 308 (2): F77–83.
14. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Failure 2016; 18 (8): 891–975.
15. Verma S, Mazer D, Fitchett D et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOMER randomised trial. Diabetologia 2018; doi.org/10.1007/s00125-018-4644-9
16. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой, А.Ю.Майорова. 8-й вып. М.: УП ПРИНТ, 2017. DOI: 10.14341/DM20171S8 / Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi, A.Iu.Maiorova. 8-i vyp. M.: UP PRINT, 2017. DOI: 10.14341/DM20171S8 [in Russian]
________________________________________________
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
3. ACCORD Study Group et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99 (12A): 21i–33i.
4. Patel A, Chalmers J, Poulter N. ADVANCE: action in diabetes and vascular disease. J Hum Hypertens 2005; 19 (Suppl. 1): S27–32.
5. Gerstein HC, Bosch J, Dagenais GR et al. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319–28.
6. White WB, Cannon CP, Heller SR et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Мed 2013; 369: 1327–35.
7. Scirica BM, Bhatt DL et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Мed 2013; 369: 1317–26.
8. Green JB, Bethel MA, Armstrong PW et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Мed 2015; 373 (3): 232–42.
9. Zinman B, Wanner C, Lachin JM. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Мed 2015; 373: 2117–28.
10. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375 (4): 323–34.
11. Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129 (5): 587–97.
12. Skrtic M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 2015; 24 (1): 96–103.
13. Lytvyn Y, Skrtic M, Yang GK et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2015; 308 (2): F77–83.
14. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Failure 2016; 18 (8): 891–975.
15. Verma S, Mazer D, Fitchett D et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOMER randomised trial. Diabetologia 2018; doi.org/10.1007/s00125-018-4644-9
16. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi, A.Iu.Maiorova. 8-i vyp. M.: UP PRINT, 2017. DOI: 10.14341/DM20171S8 [in Russian]
Авторы
И.З.Бондаренко*1, М.Г.Бубнова2
1 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России. 117036, Россия, Москва, ул. Дмитрия Ульянова, д. 11, к. 2;
2 ФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России. 101990, Россия, Москва, Петроверигский пер., д. 10, стр. 3
*iz_bondarenko@mail.ru
1 National Medical Research Center of Endocrinology. 117036, Russian Federation, Moscow, ul. Dmitriia Ul'ianova, d. 11, k. 2;
2 National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation. 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3
*iz_bondarenko@mail.ru
1 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России. 117036, Россия, Москва, ул. Дмитрия Ульянова, д. 11, к. 2;
2 ФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России. 101990, Россия, Москва, Петроверигский пер., д. 10, стр. 3
*iz_bondarenko@mail.ru
________________________________________________
1 National Medical Research Center of Endocrinology. 117036, Russian Federation, Moscow, ul. Dmitriia Ul'ianova, d. 11, k. 2;
2 National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation. 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3
*iz_bondarenko@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.